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Inhibition of acetyl-CoA carboxylase (ACC) may prevent
lipid-induced insulin resistance and type 2 diabetes, making
the enzyme an attractive pharmaceutical target. Although the
enzyme is highly conserved amongst animals, only the yeast
enzyme structure is available for rational drug design. The use
of biophysical assays has permitted the identification of a
specific C-terminal truncation of the 826-residue human ACC2
carboxyl transferase (CT) domain that is both functionally
competent to bind inhibitors and crystallizes in their presence.
This C-terminal truncation led to the determination of the
human ACC2 CT domain–CP-640186 complex crystal struc-
ture, which revealed distinctions from the yeast-enzyme
complex. The human ACC2 CT-domain C-terminus is com-
prised of three intertwined -helices that extend outwards
from the enzyme on the opposite side to the ligand-binding
site. Differences in the observed inhibitor conformation
between the yeast and human structures are caused by
differing residues in the binding pocket.
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1. Introduction
Excess accumulation of lipids in both the liver and peripheral
tissue is an important contributing factor to the development
of insulin resistance and related pathophysiologies including
diabetes, hepatic steatosis and the metabolic syndrome
(Boden, 1997; Kelley et al., 1999; Seppala-Lindroos et al.,
2002). Acetyl-CoA carboxylase (ACC) plays a pivotal role in
fat accumulation since its product, malonyl-CoA, is the first
pathway-committed precursor for de novo fatty-acid bio-
synthesis and is also a major negative regulator of fatty-acid
oxidation. For this reason, ACC is an attractive candidate for
developing drugs that target pathophysiologies related to
inappropriate fat accumulation (Harwood et al., 2003; Har-
wood, 2005; Lenhard & Gottschalk, 2002).
There are two mammalian ACC isozymes, ACC1 and
ACC2, which are transcribed by separate genes but have
discrete but related physiological roles. ACC1, which is found
largely in the cytosol, is the major isoform in lipogenic tissue
and supports fatty-acid biosynthesis. ACC2 is the predominant
form in skeletal muscle and heart and, at least in rodents, in
brown adipose tissue. In muscle and heart it is localized to the
outer mitochondrial membrane in proximity to carnitine
palmitoyl transferase 1, where it presumably functions as a
negative regulator of fatty-acid oxidation (Abu-Elheiga et al.,
2000). Bianchi and coworkers also observed ACC2 in the
cytosol in liver (Bianchi et al., 1990). Both ACC1 and ACC2
are high-molecular-weight proteins (ACC1, 265 kDa; ACC2,
275 kDa) that are 60% identical at the nucleotide level and
75% identical at the amino-acid level (Abu-Elheiga et al.,
1997). They share the same functional domains and key
regulatory phosphorylation sites, which are located in homo-
logous regions of the proteins. They differ most significantly
by the presence of an N-terminal membrane-targeting
sequence on ACC2 (Abu-Elheiga et al., 1997; Ha et al., 1996;
Harwood et al., 2003). Both are potentially attractive targets
for drug development: ACC1 from the perspective of inhi-
biting lipid accumulation and ACC2 from the perspective
of reducing lipid stores by enhancing fatty-acid oxidation.
Because the potential exists for compensatory activation of
ACC1 in response to activation of fatty-acid oxidation,
targeting both isozymes simultaneously may be beneficial. In
actuality, it may be difficult to do otherwise considering how
similar the two isozymes are to each other.
The feasibility of targeting ACC has been evaluated using
both genetic and chemical means. ACC2-knockout mice ex-
hibited enhanced fatty-acid oxidation and reduced fat storage
on a normal laboratory chow diet (Abu-Elheiga et al., 2001),
and resisted the development of obesity, insulin resistance and
glucose intolerance when placed on a high-fat diet (Abu-
Elheiga et al., 2003). Together with the fact that ACC1-
knockout mice are embryonically lethal (Abu-Elheiga et al.,
2005), these results suggest that ACC2 is the more attractive
target for treating lipid-related pathophysiologies. However,
ACC2 can support lipogenesis under some circumstances,
since ACC2 compensates for ACC1 deficiency in liver-specific
ACC1-knockout mice (Harada et al., 2007). This result is
consistent with the observation made by Bianchi and cowor-
kers that in the liver ACC2 is also a cytosolic enzyme and
suggests that the product pools of these two isozymes are not
strictly segregated and can intermix. Therefore, it is not
completely certain that the beneficial effects of knocking out
the ACC2 gene derive solely from enhanced fatty-acid
oxidation. In another genetic experiment, Savage et al. (2006)
reported that treating high-fat-fed rats with anti-ACC anti-
sense oligonucleotides improved hepatic insulin sensitivity. In
this case, suppression of both ACC1 and ACC2 was required
for the most significant effect. Finally, using a pharmacological
tool, Adler and coworkers reported that treating insulin-
resistant high-fat-fed mice with a dual ACC1–ACC2 inhibitor
(Harwood et al., 2003) ameliorated insulin resistance (Adler et
al., 2005; Harwood, 2005). Considered together, the results of
these three approaches argue that a dual ACC1–ACC2 inhi-
bitor could be an efficacious agent for lowering intracellular
lipid levels, ameliorating or preventing weight gain and
restoring insulin sensitivity.
Based on the available validation studies, we mounted a
campaign to identify high-potency ACC1–ACC2 dual inhibi-
tors with appropriate pharmokinetic properties to be useful as
therapeutic agents. Compounds were identified using a screen
based on inhibition of enzyme catalysis and were optimized by
medicinal chemistry guided by structure-based design. One
screening hit was a bipiperidine similar to that reported pre-
viously (Harwood et al., 2003). Using enzyme-inhibition
studies, Harwood and coworkers reported that CP-610431, a
molecule in this structural class, has a high probability of
binding to the carboxyl transferase (CT) domain of ACC1
(Harwood et al., 2003). To guide our optimization efforts, we
crystallized the CT domain of human ACC2 bound to com-
pounds in this chemical class and now report the first crystal
structure of a metazoan ACC CT domain.
Prokaryotic ACCs are multi-subunit enzymes with separate
proteins for the biotin carboxylase (BC) and biotin carboxyl
carrier protein (BCCP) functions and two proteins for the
carboxyl transferase (CT) function. Eukaryotes, including
yeast, have all these functions condensed within a single
polypeptide chain. The structure of the yeast ACC CT protein
answered many questions regarding the connection between
prokaryotic and eukaryotic CT functionality (Zhang et al.,
2003). Two domains within the yeast CT polypeptide were
identified that were sequentially related to the two bacterial
protein counterparts. The yeast CT polypeptide dimerizes in a
head-to-tail fashion, with an extensive interface between the
N-terminal domain of one polypeptide and the C-terminal
domain of its partner. An extensive interface between both
dimer partners and domains is consistent with the 22
organization of the functional prokaryotic CTenzyme. Further
studies revealed that the binding sites for ACC inhibitors,
including herbicides (Zhang, Tweel & Tong, 2004) and
designed compounds (Zhang, Tweel, Li et al., 2004), were all at
the dimer interface.
Sequentially, the yeast ACC CT domain is 46–52% identical
to that of other eukaryotes and starts diverging substantially
85 residues prior to the C-terminus. All metazoan ACCs are
more homologous throughout this C-terminal region. Al-
though the initial yeast ACC structures were from a construct
containing residues 1429–2233, the visible portion of the
protein included residues 1480–2196 (Zhang et al., 2003). The
yeast constructs that yielded the inhibitor structures produced
visible electron density that included residues 1482–2218
(Zhang, Tweel & Tong, 2004) and finally 1482–2195 (Zhang,
Tweel, Li et al., 2004). We found that truncating the human
ACC2 CT domain to make the equivalent construct, residues
1693–2412, yielded a protein that failed to bind the designed
inhibitors. This discovery prompted further examination of the
human ACC2 CT domain, with the goal of determining a
suitable construct for structural studies that was also compe-
tent to bind compounds. Here, we present the results of these
studies, which revealed that the C-terminal residues of human
ACC2 were necessary for compound binding. These C-term-
inal residues extend the dimer interface with a set of three
intertwined helices.
2. Materials and methods
2.1. Cloning and expression of human ACC2 carboxyl
transferase domain cDNA
A total of seven Escherichia coli ACC2 expression con-
structs with various truncations at both the N- and C-termini
were generated by PCR. The names of the constructs and the
primers used to amplify the gene are listed in Table 1.
PCR was performed with each corresponding primer pair
using an in-house human ACC2 (accession No. AAR37018)
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construct that had been codon-
optimized for E. coli expression. Each
reaction contained 2 ml (1 ng) ACC2
DNA template, 20 mM Tris–HCl pH
8.4, 50 mM KCl, 1.5 mM MgCl2, 0.2 mM
each of the four deoxyribonucleotide
triphosphates, 0.5 mM each of primers
and 0.5 unit high-fidelity Taq DNA
polymerase (Roche) in a total volume
of 50 ml. PCR amplification conditions
were 2 min of denaturation at 367 K
followed by 30 cycles of 367 K for 30 s,
333 K for 30 s and 345 K for 2 min and a
final extension step of 345 K for 15 min.
DNA bands were purified using a
Qiagen kit, digested with NdeI/XhoI
(for cloning into pET24) or BamHI/
XhoI (for cloning into pET24-MBP)
and ligated to a restricted pET24 or
pET24-MBP vector. The resulting
constructs in pET24 [ACC2 (1693–
2401), ACC2 (1693–2420), ACC2 (1693–
2441) and ACC2 (1693–2451)] con-
tained an N-terminal 6His tag with a
TEV-cleavable linker that leaves a
glycine-residue artifact after proteolysis.
The resulting construct in pET24-MBP
[ACC2 (1693–2458)] contained an
N-terminal 6His-MBP tag with a
thrombin-cleavable linker that leaves a Gly-Ser artifact after
proteolysis. Each construct was then confirmed by double-
stranded DNA sequencing.
The plasmids were transformed into BL21 (DE3) for pro-
tein expression. A single colony was picked and inoculated in
40 ml 2YT medium in the presence of 50 mg ml1 kanamycin
and incubated at 310 K until the OD600 reached 0.6; IPTG was
then added to a final concentration of 0.5 mM to induce
protein expression at 293 K overnight. Soluble protein
expression was evaluated by SDS–PAGE.
2.2. Purification of human ACC2 carboxyl transferase
domain
The cell paste was resuspended in 25 mM HEPES, 100 mM
NaCl, 20 mM imidazole pH 7.5. Cells were lysed at 277 K by
passage through a homogenizer two times at 69 MPa. The
lysate was clarified by centrifugation at 20 rev min1 in a
TZ-28 rotor (Sorvall) for 1 h followed by filtering through a
0.22 mm filter (Pall). The lysate was loaded onto a 20 ml Nickel
Sepharose FF column (GE Healthcare Biosciences) equili-
brated in 25 mM HEPES, 100 mM NaCl, 20 mM imidazole pH
7.5. Human ACC2 CT-domain protein was eluted using a
gradient of imidazole to 300 mM. Pooled fractions were
diluted threefold with 25 mM HEPES pH 7.5 and applied onto
a 22 ml Q Sepharose column (GE) equilibrated in 25 mM
HEPES pH 7.5. The protein was eluted using a gradient of
NaCl to 500 mM. Tag removal was carried out on the pooled
fractions by adding protease at a 1:100 ratio and 4 mM EDTA
and digesting overnight at 277 K. TEV protease cleavage left a
glycine residue at the N-terminus, while thrombin cleavage left
a Gly-Ser artifact at the N-terminus. The sample was desalted
on a 50 ml HiPrep Desalting column (GE) and passed back
over a 5 ml HisTrap Ni Sepharose FF column. The flow-
through was collected and applied onto a 70 ml hydroxy-
apatite column (BioRad, Ceramic, 20 mm) equilibrated in
20 mM sodium phosphate pH 7.5. The protein was eluted
using a gradient of sodium phosphate to 200 mM. Pooled
fractions were concentrated using a JumboSep 30 kDa mole-
cular-weight cutoff (Pall) and applied onto a 320 ml Superdex
200 column (GE) equilibrated in 25 mM HEPES, 200 mM
NaCl pH 7.5. Pooled fractions were concentrated to 5–
7 mg ml1 using a CentriPrep YM-10 (Millipore) and deliv-
ered fresh at 277 K. Optimal results were not obtained using
frozen samples.
2.3. Circular-dichroism spectroscopy
An Aviv 62DS/202.01 circular-dichroism spectrometer was
used to measure the ellipticity at 222 nm as a function of
temperature using a five-position Peltier-controlled sample
holder. Measurements were made in 0.1 cm path-length quartz
cuvettes with a sample volume of 0.3 ml. The ACC2 concen-
tration was 4–7 mM in PBS. Compounds were dissolved in
ethanol prior to their addition to the protein samples and
equivalent volumes of ethanol were added to the samples
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Table 1
Construct names and primers.
Construct name Vector Primer sequence































containing protein only. Thermal transitions were analyzed by






1þ exp½ðTm  tÞ=dt
þmin222 nm;
where t222 nm is the ellipticity at 222 nm at temperature t,
min222 nm and 
max
222 nm are the minimal and maximal ellipticities at
222 nm, respectively, Tm is the midpoint of the thermal tran-
sition and and dt is the steepness of the transition.
2.4. SYPRO Orange dye binding
A PerkinElmer ABI Prism 7700 Sequence Detector was
utilized to monitor the fluorescence emission intensity of
SYPRO Orange dye as a function of temperature. Standard
96-well PCR plates with optical plastic covers were used in
these experiments. Each well contained a final volume of 40 ml;
the final concentration of purified ACC2 was 1–2 mM, the
SYPRO Orange dye (5000 stock in DMSO) was diluted
50-fold in DMSO and 0.4 ml of this working dilution was used
in each well. The dye was added to the protein stock solution
prior to filling the plate, into which the compounds to be tested
had been previously dispensed. Compounds were added in
DMSO, either to result in one test concentration, usually
10 mM, or as a serial dilution in DMSO. Compounds were
dispensed at 100 in DMSO, resulting in another 0.4 ml of
DMSO per well, which brought the final DMSO concentration
to 2%(v/v). A small effect of DMSO on the thermal transition
temperature of ACC2 was observed over the range 0–6%(v/v)
DMSO (an increase of 0.4 K at 2%); therefore, all measure-
ments, with or without compound, were made with the same
final DMSO concentration of 2%(v/v). Thermal transitions





1þ exp½ðTm  tÞ=dt
þ Fltpre;
where Flt is the fluorescence intensity at temperature t, Fltpre
and Fltpost are the minimal and maximal fluorescence inten-
sities at temperature t, respectively, Tm is the midpoint of the
thermal transition and dt is the steepness of the transition.
Fltpre and Fl
t
post were treated as linear functions of temperature,
where Fltpre = m1 t + b1 and Fl
t
post = m2 t + b2, where m1, b1
and m2, b2 are the slope and y intercept of the pre-transition
and post-transition baselines at temperature t, respectively.
This modification accounts for nonzero slopes in the baselines
of the fluorescence data.
2.5. Crystallization of human ACC2 carboxyl transferase
domain
All human ACC2 CT-domain crystallization trials were
performed with protein in the buffer from the final purification
step (25 mM HEPES pH 7.5, 200 mM NaCl). All successful
crystallization trials also required the addition of a coenzyme
A analogue to the protein solution. For example, acetyl co-
enzyme A was added to the human ACC2 CT domain [ACC2
(1693–2451)] solution to a final concentration of 2 mM (from a
100 mM stock in 10 mM HEPES pH 7.5) and the complex was
concentrated to 15 mg ml1 using a CentriPrep YM-3 (Milli-
pore) to produce the protein solution used for the crystal
structures reported here. In separate trials, 2 mM acetyl co-
enzyme A, acetoacetyl coenzyme A, butyryl coenzyme A or
malonyl coenzyme A (Sigma) were added to the human ACC2
CT-domain [ACC2 (1693–2451)] solution in attempts to
optimize crystal diffraction. Although clear electron density
for cofactors was never observed, optimization of crystals
containing proprietary compounds suggested that better
diffraction data were consistently obtained when 2 mM
malonyl coenzyme A was substituted in place of 2 mM acetyl
coenzyme A.
Initial crystals of the ACC2–acetyl coenzyme A complex
were obtained in Index Screen (Hampton Research) condition
No. 88 [20%(w/v) PEG 3350, 0.2 M triammonium citrate pH
7.0] by hanging-drop vapor-diffusion equilibration in 96-well
Neuro Probe trays (Neuro Probe Inc.) using 0.3 ml protein
solution and 0.3 ml well solution. Optimized crystals of the
ACC2–acetyl coenzyme A complex or the ACC2–malonyl
coenzyme A complex were grown by mixing 2 ml protein
solution with 2 ml well solution and equilibrating using
hanging-drop vapor diffusion at 295 K in 24-well trays
containing 1 ml crystallization solution in the well. All trays
employed a reagent-concentration grid around the observed
crystallization conditions containing 17–22%(w/v) PEG 3350,
0.1–0.25 M triammonium citrate pH 7.0 and 5%(v/v) glycerol.
Initial crystal optimization produced clusters of multiple thin
plates that were manually crushed into microcrystal seed stock
and stored in 30 ml 20%(w/v) PEG 3350, 0.2 M triammonium
citrate pH 7.0 and 5%(v/v) glycerol. Another round of opti-
mization used the same protocol as described above, but with
microcrystals streak-seeded into the crystallization drops
using a horse hair. Microseeding produced large single plates
(0.5  0.35  0.1 mm) that took three weeks to grow. These
crystals were extremely fragile and required vapor-diffusion
fixation with glutaraldehyde (Lusty, 1999) for 15 min prior to
further handling. Apo crystals were quickly dunked into well
solution plus 25%(v/v) ethylene glycol and plunge-frozen in
liquid nitrogen.
Compounds, including CP-640186, were soaked into cross-
linked crystals using the following protocol. Cross-linked
crystals were placed into a 4.5 ml drop of harvest solution
[20%(w/v) PEG 3350, 0.2 M triammonium citrate pH 7.0 and
5%(v/v) glycerol] and 0.5 ml 20 mM compound in DMSO was
added to the drop to give a final compound concentration of
2 mM. The harvest-solution drop containing the crystals and
compound was suspended over 1 ml harvest solution for 5 h
using a single well from a hanging-drop tray. Crystals were
removed from the harvest drop, quickly dunked into harvest
solution plus 25%(v/v) ethylene glycol and plunge-frozen in
liquid nitrogen.
2.6. Crystal structure determination and refinement
An initial 3.6 Å data set for apo human ACC2 CT domain
was collected using a Rigaku 007HF rotating-anode X-ray
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generator (Rigaku USA) with a MAR345 DTB imaging-plate
detector (MAR USA). This data set provided the initial
crystal parameters; an orthorhombic space group with unit-
cell parameters a = 82, b = 171, c = 295 Å. Using a molecular
weight of 86 037 Da, the Matthews coefficient suggested the
presence of four molecules per asymmetric unit. Molecular
replacement was carried out using the program MOLREP
(Vagin & Teplyakov, 1997) and confirmed that the space group
was P212121. The search model was composed of a monomer
of the yeast ACC CT domain (PDB code 1uyr; Zhang, Tweel
& Tong, 2004) truncated to span residues 1482–2133. This
procedure correctly located three of the four subunits and
confirmed that the human ACC2 CT domain formed a dimer
with a similar interface as observed for the yeast protein. A
fourth monomer was placed manually to act as the dimer
partner for the third monomer, which further reduced the R
factor and accounted for the extensive positive difference
density. No building or refinement was performed using this
data set.
The large unit-cell edge of the crystal form suggested that
the lower mosaicity from a smaller beam obtained at a
synchrotron might improve diffraction quality. Diffraction
data collected at the Southeast Regional Collaborative Access
Team (SER-CAT) and the General Medicine/Cancer (GM/
CA) CAT at the Advanced Photon Source (APS) confirmed
this suspicion, with the mosaicity dropping by 0.5. A 3.4 Å
data set from crystals of apo human ACC2 CT domain was
collected on SER-CAT 22-BM at the APS and was used for
building and refinement. A starting human ACC2 model was
built from a monomer of the truncated yeast protein (Zhang,
Tweel & Tong, 2004) using Swiss-PDB
Viewer (Guex & Peitsch, 1997) to
incorporate the human numbering and
sequence. Monomers were positioned
by molecular replacement using the
program MOLREP (Vagin &
Teplyakov, 1997) followed by rigid-body
refinement and fourfold electron-
density map averaging using noncrys-
tallographic symmetry. The human
protein model was refined against this
data set using CNX2002 (Brünger et al.,
1998) and built using QUANTA05
(Morris, 2004). Strict four-
fold noncrystallographic symmetry was
enforced for the first round of refine-
ment and strict twofold noncrystallo-
graphic symmetry was enforced for the
next two rounds, followed by non-
crystallographic restraints. The apo
protein was refined to R = 23.1, Rfree =
28.4 with r.m.s.d.s from ideality of
0.009 Å and 1.4 for bond lengths and
angles, respectively. The final model
contained four copies of the human
ACC2 CT domain spanning residues
1695–2449 and no water molecules.
The 3.19 Å resolution ACC2 CT domain–CP-640186
complex data were collected on GM/CA CAT 23-IDD at the
APS and the structure was solved by molecular replacement
using the human apo structure. The model was further refined
to R = 21.8, Rfree = 26.8 using REFMAC5 (Murshudov et al.,
1997) and built using Coot (Emsley & Cowtan, 2004). The final
model contained four protein molecules, four molecules of
CP-640186 and 76 water molecules. The r.m.s.d.s from ideal
geometry were 0.007 Å and 1.4 for bond lengths and angles,
respectively. Fourfold noncrystallographic symmetry
constraints were not imposed on this structure. All four copies
of the CP-640186 molecule were independently placed into 3
difference density using the ligand-fitting feature in Coot and
refined independently. Data-collection and processing statis-
tics are summarized in Table 2.
3. Results
3.1. Yeast sequence similarity to animal and human ACCs
Our major objective was to use the human ACC2 CT
domain in the rational design of potent selective inhibitors.
Prior to this study, only the yeast ACC had yielded a publicly
available eukaryotic ACC structure, and the possibility existed
that differences in compound binding result from sequence
differences between yeast and human. Overall, the yeast ACC
has 45% pairwise-sequence identity to animal ACCs, with
46–52% pairwise sequence identity in the CT domain.
However, the C-terminal 85 residues of yeast ACC are 13%
identical to those of animal ACCs. Human ACC2 is more
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Table 2
X-ray data-collection and refinement statistics for human ACC2 CT-domain structures.
Values in parentheses are for the highest resolution shell.
Apo protein CP-640186 complex
Data collection
X-ray source APS 22-BM APS 23-IDD
Wavelength (Å) 1.0 1.0
Space group P212121 P212121
Unit-cell parameters (Å) a = 82.4, b = 170.8,
c = 296.6
a = 82.3, b = 170.7,
c = 295.4
Resolution range (Å) 20.0–3.4 (3.55–3.4) 20.0–3.19 (3.27–3.19)
Observations 194635 2507021
Unique reflections 54871 64397
Redundancy 7.0 7.5 (7.5)
Completeness (%) 94.1 (95.1) 99.9 (99.9)
hI/(I)i 10.6 (4.0) 13.1 (4.8)
Rmerge† (%) 12.3 (44.6) 11.0 (45.7)
Refinement statistics
R factor‡ (%) 23.1 (33.0) 21.8 (29.4)
Rfree‡ (%) 28.4 (35.0) 26.8 (37.8)
No. of protein/water atoms 22847/0 22930/76
R.m.s.d. bond distances (Å) 0.010 0.007
R.m.s.d. bond angles () 1.42 0.954
Wilson B value (Å2) 55.0 46.4
Average protein B value (Å2) 57.8 40.3
Ramachandran plot
Most favored ’ and  angles (%) 87.0 94.9














was calculated for a randomly chosen 7% of reflections in both structures.
typical of animal ACCs. Overall, human ACC2 shows 58–88%
pairwise sequence identity to animal ACCs, with similar (60–
87%) pairwise sequence identity within the CT domain.
Within the last 85 residues, human ACC2 has 30% pairwise
sequence identity to arthropod ACCs and 52–75% identity to
other mammalian ACCs (Fig. 1). Thus, the yeast ACC is
similar to the animal enzyme overall, but there are regions,
notably the C-terminus, that contain significant divergence. It
was necessary for us to determine whether these differences
produced significant systematic changes to the compound-
binding pocket that might influence drug-discovery efforts.
Initial attempts at crystallizing the human ACC2 CT
domain used the full domain, residues 1693–2458, and
produced no crystals. The yeast structures were then used to
provide guidance for designing further constructs. The frag-
ment of yeast ACC CT domain bound to the synthetic inhi-
bitor CP-640186 included residues 1476–2233, but the
structure only included residues 1482–2195 (Zhang, Tweel, Li
et al., 2004), equivalent to human residues 1693–2412. When
the human ACC2 was truncated to include the conserved
amino acids, residues 1693–2401, or the visible residues, 1693–
2420, no crystals were obtained. At this point, a more careful
examination of the protein’s functional properties was initi-
ated, with the results of these experiments guiding further
construct selection.
3.2. Functional selection of human ACC2 carboxyl
transferase domain
The carboxyl transferase domain of human ACC2 was a
target for structural determination, specifically in complex
with inhibitors, in order to enable and facilitate structure-
guided chemistry efforts. Unfortunately, this isolated domain
lacks much of the enzymatic activity that was measured for
full-length ACC2, so measurement of direct binding of inhi-
bitors was required in order to select an appropriate construct
for structural determination.
Progressively truncated constructs of the carboxyl trans-
ferase domain of human ACC2 were engineered, expressed
and purified as described above. Several approaches were
used to assess the ligand-binding competence of these con-
structs. The objective was to identify the smallest domain
construct which retains inhibitor binding and to use that
construct for crystallography.
3.2.1. Fluorescence polarization assay for compound
binding. A known inhibitor of the catalytic activity of full-
length human ACC2, CP-640188, has intrinsic fluorescent
properties, making it suitable for use as a direct ligand-binding
reagent, as detected by changes in its fluorescence polarization
when bound to ACC2.
CP-640188 (Fig. 2a) has an excitation maximum at 365 nm
and an emission maximum at 413 nm. Using these wave-
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Figure 1
Sequence comparison between animal and yeast ACC CT-domain C-termini. Residues identical to the human protein are shaded green. Residues
involved in the dimer interface are shown in solid black boxes. Residues making visible contact in only one dimer are shown in dashed black boxes.
Proline residues facilitating the kinking of the terminal helices are surrounded by a blue box. The sequences compared are Homo sapiens ACC2
(hACC2; accession No. AAR37018), Mus musculus ACC2 (mACC2; accession No. NP_598665), Rattus norvegicus ACC2 (rACC2; accession No.
NP_071529), Gallus gallus ACC (cACC; accession No. AAA48701), H. sapiens ACC1 (hACC1; accession No. NP_942131), M. musculus ACC1 (mACC1;
accession No. AAS13685), Anopheles gambiae ACC (agACC; accession No. XP_314071), Drosophila melanogaster ACC (dmACC; accession No.
NP_610342) and Saccharomyces cerevisiae ACC (yACC; accession No. NP_014413).
lengths, the polarization of the free ligand was measured and
this polarization increased as human ACC2 carboxyl terminal
domain (1693–2458) was titrated (Fig. 2b). Fitting this binding
curve to a standard isotherm resulted in an apparent Kd of
1.2 mM for ACC2 binding to CP-640188. Other inhibitors,
such as GSK723A, were shown to displace the fluorescent CP-
640188 (Fig. 2c). Fitting these displacement curves resulted in
an apparent Kd of 5.6 mM for GSK723A competition of CP-
640188 from ACC2. Similarly, a truncated form of human
ACC2 carboxyl transferase domain (1693–2451) could be used
to titrate the ligand polarization and other inhibitors,
GSK723A and GSK193A, were also shown to displace the
fluorescent CP-640188 (Fig. 2d).
3.2.2. Thermal stability assay for compound binding to
human ACC2 CT domain. Thermodynamically, the binding of
a small-molecule ligand to a protein results in a net decrease in
the free energy of the system. This is reflected in a stabilization
of the protein–ligand complex relative to the protein alone;
that is, more energy (i.e. a higher temperature) is required to
unfold the protein–ligand complex than for the protein alone.
Two methodologies were used to assess the ligand-depen-
dent thermal stability of human ACC2 CT domain in vitro:
circular-dichroism spectroscopy (CD) and fluorescent-dye
binding. In this application, both of these techniques measure
optical changes as a function of increasing temperature and
both of those signals are sensitive to the unfolding of protein
in response to heating. CD directly monitors a protein’s
secondary-structural composition, most notably the -helical
content. By observing the CD signal at a characteristic
wavelength, 222 nm, with increasing temperature, the loss of
-helical structure can be measured. This is representative of
the overall folding and thus the stability of the protein. The
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Figure 2
Fluorescence polarization and anisotropy measurements of ligand binding to the human ACC2 CT domain. (a) The structures of CP-640188 and CP-
640186, which were used to establish the fluorescence and thermal melting assays for ligand binding and as a complex for crystal structure determination,
respectively. (b) Saturable fluorescence polarization signal (excitation at 365 nm, emission at 413 nm) obtained by titrating 1 mM CP-640188 with human
ACC2 (1693–2458). (c) 1 mM ACC2 (1693–2458)/1.5 mM CP-640188 polarization (triangles) and anisotropy (circles) signals decrease when competed
with nonfluorescent GSK723A. (d) Fluorescence polarization (black) and anisotropy (white) for the active ACC2 truncation (1693–2451) at 1 mM; 1 mM
CP-640188 was present for all measurements except ‘ACC2/malCoA only’, which shows the background fluorescence polarization signal. ‘PBS’
represents the fluorescence polarization signal for 1 mM CP-640188 in the absence of ACC2 protein. ACC2L is ACC2 (1693–2458). ‘ACC2/malCoA’ is
ACC2 (1693–2451) complexed with malonyl-coenzyme A and where indicated GSK723A and GSK193A are competing ligands present at 10 mM.
other technique depends upon the fluorescent properties of a
dye, SYPRO Orange, which preferentially binds to exposed
hydrophobic regions of proteins. Exposure of this dye to a
hydrophobic environment results in an increase of its relative
fluorescence emission. When a protein unfolds, i.e. in response
to heating, its hydrophobic core becomes exposed to solvent
and to SYPRO Orange dye binding if present. Similarly to
that described above for CD, observation of the fluorescence
signal at a specific emission wavelength with increasing tem-
perature can be used to monitor the unfolding and thus the
stability of the protein.
CP-640188 was observed to shift the thermal transition of
the ACC2 carboxyl transferase domain construct (1693–2451)
by 10–14 K at saturation (Fig. 3a). The ability of this ligand to
stabilize ACC2 was lost as the constructs were progressively
truncated, indicating that the shorter constructs were not able
to bind this inhibitor (Fig. 3b). The smallest construct made
which retained measurable CP-640188 binding was (1693–
2451), therefore making it most suitable for crystallography.
Human ACC2 (1653–2451) carboxyl transferase domain
was titrated with three known ACC2 inhibitors: CP-640188,
GSK723A and GSK193A (Fig. 3c). All three of these ligands
increased the thermal transition of this ACC2 carboxyl
transferase domain by 7–10 K at saturation, indicating that
this construct was competent to bind various inhibitors. Fitting
of these binding curves to a standard isotherm resulted in
apparent Kd values of 1.1 mM for CP-640188, 0.8 mM for
GSK723A and 2.2 mM for GSK193A. These values are
presented as ‘less than or equal to’ () because the experi-
mental conditions impose a tight binding limit owing to the
relatively high protein concentration required for these
measurements. Having the ability to bind different chemical
entities offered increased confidence in the selection of this
construct for the pursuit of crystallography of ACC2 com-
plexes.
3.3. The crystal structure of human ACC2 CT domain shows a
novel C-terminus
The determination that hACC2 (1653–2451) was function-
ally competent to bind compounds paralleled its successful
application in crystallization trials. This ACC2 CT construct
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Figure 3
Thermal denaturation is influenced by ligand binding to human ACC2 CT domain. (a) A reproducible and saturable increase in the melting temperature
of ACC2 (1693–2451) (circles) is observed when 13 mM (gray diamonds) and 50 mM (triangles) CP-640188 is added to 4.4 mM human ACC2. (b) The
compound-induced shift (triangles) in the midpoint of the CD thermal transition of ACC2 (circles) is retained when seven residues are truncated but lost
when 17 residues are truncated from the C-terminus. ACC2 was at 4–7 mM and where indicated CP-640188 was present at 33–50 mM. Lines are drawn
only to indicate trends. (c) Multiple compounds induce a titratable melting-temperature shift in ACC2 (1693–2451). ACC2 at 1–2 mM was titrated with 0–
10 mM CP-640188 (circles), GSK723A (squares) and GSK193A (triangles) and subjected to thermal denaturation in the presence of (1) SYPRO
Orange fluorescent dye. The resulting Tm values from fitted curves are plotted against compound concentration.
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was crystallized as a complex with CP-640186 (CP186; Fig. 2a)
in 25%(w/v) PEG 3350, 5%(v/v) glycerol and 0.2 M tri-
ammonium citrate pH 7.0. Crystal formation required the
presence of a coenzyme A derivative (e.g. acetyl or malonyl)
in the crystallization solution, but good electron density for
this cofactor was never observed. However, interpretable
electron density was observed for both the ligand and the
C-terminus of the protein.
The model used to determine the structure of the human
ACC2 CT domain was built from the yeast structure and only
included the sequentially conserved residues 1482–2133
(human 1693–2337). Nevertheless, the electron density
generated from the original molecular-replacement phases
indicated that the protein extended substantially past the
model terminus (Fig. 4a). Using the observed noncrystallo-
graphic symmetry to average this electron density (Fig. 4b)
Figure 4
Electron density is observed beyond the C-terminus of the molecular-replacement search model. (a) Electron density for the C-terminal region is
observed immediately following molecular replacement with yeast ACC CT domain (PDB code 1uyr) (red). A ribbon showing the final human structure
is shown for comparison (yellow). (b) The C-terminal electron density was improved by fourfold noncrystallographic averaging based on the positions of
the conserved protein residues. (c) The electron density surrounding one of the C-terminal regions in the final refined model. All electron-density maps
are contoured at 1.
revealed a series of three intertwined helices that extended to
residue 2449 (Fig. 4c). These three helices extend outward
from the bulk of the protein complex (Figs. 5a and 5b) and are
flexible. Despite their flexibility, elimination of any part of this
structure resulted in a protein that was functionally unable to
bind compound.
The contacts between the C-terminal helices (Fig. 5b) are
maintained by the amphipathic nature of the sequence and the
kinking is facilitated by two prolines: Pro2423 and Pro2439.
The flexibility of the helices led to a loss of the strict twofold
symmetry of the protein complex at the C-terminus, as well as
during the overlay between noncrystallographically related
molecules. This lack of symmetry provides the caveat that the
conformational details may be influenced by crystal packing.
Fortunately, there was sufficient mass superimposition to yield
improvement during the initial fourfold electron-density
averaging. These additional helices only increased the size of
the dimer interface by 293 Å2 per molecule, but many of the
side chains were not visible in the crystal structure. The final
helix started at residue 2439, just prior to the longest non-
binding construct. Although we know that these C-terminal
helices are necessary for compound binding, we have not
directly measured their effect on domain dimerization.
The human ACC2 CT-domain structure also contains resi-
dues 2252–2284 (yeast 2048–2080) which were not present in
the search model (Figs. 5a and 5c). As was the case for the
C-terminal residues, the electron density was visible in the
initial molecular-replacement map (Fig. 6a), the helical
secondary structure was defined after fourfold noncrystallo-
graphic averaging (Fig. 6b) and the final map positioned the
residues and allowed the turn to be built (Fig. 6c). The final
average refined B factor for this loop is 48.3 Å2, which is
comparable to that of the entire protein. This stretch con-
tinues from the previously observed -helix initiated at
residue 2241 (yeast 2037) until Pro2253 generates a right-angle
turn outward from the protein dimer. The next stretch of
residues (2254–2284) forms a pair of antiparallel amphipathic
-helices separated by a three-residue turn following Pro2265.
The two helices are pinned together at the proximal ends by a
hydrogen bond between Tyr2255 and Glu2283 and a salt
bridge between Asp2252 and Arg2282 (Fig. 5c).
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Figure 6
Electron density is observed for a loop spanning residues 2252–2284 of the human ACC2 CT domain that was not present in the molecular-replacement
search model. A stick representation showing the final human structure is shown for comparison (yellow). (a) Electron density for the loop is observed
immediately following molecular replacement with yeast ACC CT domain (PDB code 1uyr). (b) The electron density is improved by fourfold
noncrystallographic averaging based on the positions of the yeast protein residues. (c) The electron density surrounding a representative loop in the final
refined model. All electron-density maps are contoured at 1.
Figure 5
Comparison between the human and yeast ACC CT domains. (a) This cartoon diagram
shows the human ACC2 CT-domain dimer (light and dark red protein, orange ligand)
superimposed on the structure of the yeast ACC CT domain (light and dark blue protein,
blue ligand). The C-terminal region and antiparallel helical extensions are indicated. (b)
A detailed view of one copy of the flexible C-terminus is included. Sequence limits for the
three helices are given and prolines at the helical kinks are shown with thick bonds. (c)
The residues responsible for the folding of the antiparallel helical extensions are
indicated.
3.4. Compounds bind to the human ACC2 CT domain at the
dimer interface
The binding mode and pocket surrounding CP186 in the
human ACC2 CT domain closely resembled those of the yeast
ACC CT domain (Fig. 7a). As observed in the yeast ACC
structure, CP186 binds at the dimer interface and interacts
with residues from both copies of the ACC2 protein. The large
anthracene moiety is not surrounded by hydrophobic residues,
but by flexible polar residues that adopt rotamers pointing the
polar groups away from the ligand. Although there are resi-
dues with polar side chains surrounding the ligand, the only
two polar interactions are with the protein main chain: a
hydrogen bond between the carbonyl adjacent to the anthra-
cene and the main-chain amide N atom of Glu2230 (yeast
Glu2026) and a weak hydrogen bond between the carbonyl
adjacent to the morpholine and the main-
chain amide N atom of Gly2162 (yeast
Gly1958). Otherwise, the C-shaped mole-
cule simply fits nicely into a complementary
pocket shape formed by the surrounding
residues.
Of the 22 residues surrounding the ligand
at a distance of less than 5 Å, six differ
between human and yeast, including the
substitution of Leu1965 for Ile1762, Val1968
for Met1765, Ala2125 for Pro192, Phe2130
for His1925, Glu2232 for Gln2028 and
Glu2236 for Gly2032 (Fig. 7). Although
those changes did not substantially change
the binding mode for this compound, the
conformations of the piperidine and the
terminal morpholine differed from the yeast
structure in all four copies of CP186 observed in human
ACC2. This is a significant result because all four molecular
copies of CP186 were individually placed into 3 difference
density and the complex was refined without noncrystallo-
graphic constraints. Thus, the observed difference in ligand
conformation appears to be a direct consequence of the
residue substitution on both sides of the morpholine. The
substitution of Ala2125 for yeast Pro1920 creates space on one
side of the morpholine ring, while the substitution of Leu1965
for yeast Ile1762 reduces space on the other. This suggests that
subtle changes in the pocket shape and surface polarity may
lead to differences in compound binding to yeast and human
ACCs.
4. Summary and implications for drug discovery
Acetyl-coenzyme A carboxylase (ACC) is responsible for the
pivotal step in fatty-acid anabolism: the synthesis of malonyl-
CoA from acetyl-CoA. The diseases associated with fatty-acid
accumulation, such as insulin resistance, diabetes and meta-
bolic syndrome, suggest that ACC is an attractive target for
regulating this pathway by small molecules. Previous chem-
istry efforts (Harwood et al., 2003) demonstrated that ACC
could be inhibited by small molecules and structural efforts
(Zhang, Tweel, Li et al., 2004) identified a unique binding site
in the CT domain. Although the residues surrounding the
compound are similar in the yeast and human ACCs, human
ACC2 did not bind compound when truncated to the
equivalent size protein in the yeast structure. We suspected
that the C-terminal sequence divergence between yeast and
metazoan ACC may play a role in this functional distinction
and mutagenesis combined with compound-binding assays
bore out this notion.
Two methods were identified for measuring compound
binding to the human ACC2 CT domain, a direct binding
method utilizing the intrinsic fluorescence of the anthracene
moiety in CP-640188 and a thermal melting assay that
measured the stability imparted to the protein by compound
binding. Both methods indicated that a seven-residue
C-terminal truncation was tolerated for compound binding
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Figure 7
Stereo figure showing the comparison of CP-640186 binding to human (pink) and yeast (cyan)
ACC CT domains. Residues that differ sequentially between yeast and human and that contact
the ligand are indicated with thick bonds. Hydrogen bonds are indicated by magenta dashed
lines.
Figure 8
The acetyl-coenzyme A moiety binds in a pocket immediately adjacent to
the ligand CP186. The yeast structure with acetyl-coenzyme A (PDB code
1od2; Zhang et al., 2003) was superimposed on the human ACC2–CP186
structure (pink and magenta ribbon and C atoms) to show the relative
positions of the inhibitor (orange C atoms) and cofactor (blue C atoms).
but a 17-residue C-terminal truncation produced protein
unable to bind compound. Thus, the window for crystallization
success was within a ten-residue segment of an 826-residue
protein, representing fairly tight constraints on construct
design. Performing the functional assays led to the identifi-
cation of useful constructs before protein scale-up, purification
and crystallization trials. Thus, up-front small-scale construct
functional assaying represents a successful strategy for
medium-throughput triaging prior to committing to a lengthy
crystallization campaign.
As expected, the overall fold of the human ACC2 CT
domain was similar to that of yeast with the exception of the
C-terminus, where animal ACC sequences differ significantly
from that of yeast. Human ACC2 terminated in a series of
three intertwined -helices extending out from the bulk of the
ACC dimer. The unique conformation of this C-terminal
structure is maintained by the amphipathic nature of the -
helices and a pair of prolines in the terminal sequence that
facilitates the directional changes. These helices were very
mobile in the crystal structure, with average B factors that
were 60 Å2 higher than that of the entire protein. However,
they were clearly visible in the unbiased electron density
obtained while solving the structure and are present in all
refined structures. The high pairwise sequence identity in the
terminal residues suggests that this structure is maintained
amongst the other animal ACCs. In fact, the two prolines that
permit the intertwining are conserved in all animal ACCs but
do not exist in the yeast protein (Fig. 1).
Functional studies demonstrated that the ability of human
ACC2 to bind compound depended on the correct folding of
the C-terminal helices, but we do not know whether this
functional dependence is maintained throughout the animal
kingdom. The observed functional dependence is somewhat
surprising given that the C-terminus is located on the opposite
side of the complex from the ligand-binding site. One possible
explanation lies in the fact that the ligand binds at the dimer
interface, which may be modified or stabilized by the
C-terminal structure. If true, the effect must indeed be subtle
as it had no clear impact on the protein’s melting temperature.
By comparison, ligand binding raised the melting temperature
by 16 K. The propensity to bind ligand is clearly related to
crystallization, as the shorter functionally dead constructs did
not yield crystals. Unfortunately, without the nonfunctional
structures for comparison, the mechanism by which the
C-terminus of the animal ACCs imparts functionality from the
opposite side of the molecule is unresolved.
Another unresolved effect was the requirement of a CoA
derivative for crystallization. No crystals were obtained in the
absence of any CoA and the use of different CoA derivatives
(e.g. acetyl, malonyl etc.) during crystallization had an impact
on diffraction quality. Despite numerous cocrystallization and
crystal-soaking attempts with millimolar concentrations of
CoA derivatives, the phases resulting from the refined crystal
structures only produced patchy electron density in the pocket
adjacent to CP186, where acetyl-CoA was built into the yeast
structure (Fig. 8; Zhang et al., 2003). Superimposition of this
structure with the human ACC2–CP186 complex suggests that
the CoA cofactors are almost in direct contact with the inhi-
bitor and might share several contact residues, such as
Thr1960, Leu2229 and Ile2237.
Successful elucidation of the human ACC2 structure con-
firmed the binding site for CP186 observed in yeast ACC and
also illustrated some potential problems modeling compound
binding because of amino-acid differences between human
and yeast. Adjacent to the CP186 anthracene moiety the yeast
ACC has a short flexible Gly2032 and a neutral Gln2028. In
contrast, the human ACC2 has two negatively charged
glutamic acids (2232 and 2236) in the same positions. For this
ligand, glutamic acids 2232 and 2236 adopt rotamers that point
their charged groups away from the anthracene and towards
His2291 and Arg2240, respectively. At the other end of the
ligand pocket, three hydrophobic residue substitutions subtly
change the pocket shape: Leu1965 for yeast Ile1762, Val1968
for yeast Met1765 and Ala2125 for yeast Pro1920. CP186 is
anchored by the large anthracene at one end and two main-
chain hydrogen bonds throughout the molecule. Diverse
compounds with various anchor points may interact differ-
ently with pocket residues and these differences could be
magnified or lead to distinct binding modes when comparing
yeast and human structures.
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